⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NTLA News
Intellia Therapeutics, Inc
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
NTLA
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
prnewswire.com
NAGE
OCGN
NTLA
GERN
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
globenewswire.com
NTLA
Form 8-K
sec.gov
NTLA
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
globenewswire.com
NTLA
Form 8-K
sec.gov
NTLA
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
globenewswire.com
NTLA
Intellia Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
NTLA
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
globenewswire.com
NTLA
Growth Factors Market to Reach US$ 3.7 Bn by 2033, Expands Amid Rising Regenerative Medicine and Biopharmaceutical Innovation - Persistence Market Research
prnewswire.com
TMO
MRK
BIO
BIIB
AMGN
GILD
REGN
CRSP
NTLA
BMY
ABBV
AZN
NVS
PFE
JNJ
MRNA
BNTX
COR
STEM
ALGN
EXAS
MDLZ
BHC
CVS
UNH
CI
CNC
ELAN
ZTS
ISRG
QRVO
SWKS
AVGO
QCOM
INTC
MSFT
GOOG
AMZN
IBM
ORCL
CRM
ADBE
NFLX
DIS
MCD
SBUX
KO
PEP
PG
JPM
BAC
WFC
C
GS
MS
AXP
V
MA
HD
LOW
COST
TGT
WMT
BBY
CMCSA
VZ
T
XOM
CVX
SIRI
UBER
LYFT
NVDA
AMD
MU
AMAT
LRCX
ASML
ADI
TXN
QGEN
ILMN
VRTX
EDIT
BEAM
SRPT
ACAD
ALKS
MDT
SYK
DHR
GOOGL